Day One Biopharmaceuticals Inc. is a holding company that specializes in developing and commercializing targeted therapies for genetically defined cancers in patients of all ages. The company’s research and development efforts have culminated in two promising products, DAY101 and pimsertib.

Our Mission

Our primary goal is to help patients with genetically defined cancers by providing them with more personalized and effective treatments. We believe that genetic testing can play a vital role in the diagnosis and treatment of cancer, and we are committed to being at the forefront of this field.

Our Products

DAY101 is an oral small molecule that inhibits a protein known as SF3B1. This protein is frequently mutated in certain types of cancer, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL). By inhibiting SF3B1, DAY101 can selectively kill cancer cells while leaving healthy cells unharmed. We are currently conducting clinical trials to evaluate the safety and efficacy of DAY101 in patients with MDS, AML, and CLL.

Pimsertib is a potent and selective inhibitor of a protein called MEK. This protein is involved in many different signaling pathways that are frequently altered in cancer. By inhibiting MEK, pimsertib can impair the growth and survival of cancer cells. We are currently conducting clinical trials to evaluate the safety and efficacy of pimsertib in patients with solid tumors that have a specific genetic alteration known as a KRAS mutation.

Our Founders

Day One Biopharmaceuticals Inc. was founded by Julie Grant and Samuel Blackman in November 2018. Ms. Grant is an experienced biotech executive who previously served as the chief executive officer of Kura Oncology. Mr. Blackman is a veteran drug developer who has held leadership positions at several prominent biotech companies, including Genentech and Plexxikon. Together, they bring a wealth of knowledge and experience to our company.

Our Headquarters

Day One Biopharmaceuticals Inc. is headquartered in Brisbane, California, a small city located just south of San Francisco. Our location provides us with easy access to some of the world’s leading biotech and pharmaceutical companies, as well as to a highly skilled workforce.

Conclusion

At Day One Biopharmaceuticals Inc., we are driven by a passion for helping patients with genetically defined cancers. Our innovative products, DAY101 and pimsertib, have the potential to make a real difference in the lives of these patients, and we are committed to advancing them as quickly and safely as possible. We believe that our focus on personalized medicine and genetic testing will be a key to our success, and we are excited about the future of our company.